"Oligonucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)
| Descriptor ID |
D009841
|
| MeSH Number(s) |
D13.695.578.424
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides".
This graph shows the total number of publications written about "Oligonucleotides" by people in this website by year, and whether "Oligonucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 2 | 4 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 5 | 6 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2018 | 4 | 0 | 4 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 3 | 1 | 4 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligonucleotides" by people in Profiles.
-
Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020 10; 62(4):550-554.
-
Regulation of receptor tyrosine kinases by miRNA: overexpression of miRNA using lentiviral inducible expression vectors. Methods Mol Biol. 2015; 1233:135-47.
-
Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev. 2015 Jan; 81:104-16.
-
Precisely tunable engineering of sub-30 nm monodisperse oligonucleotide nanoparticles. J Am Chem Soc. 2014 Jan 08; 136(1):234-40.
-
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 01; 19(23):6578-84.
-
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
-
Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
-
A peroxidase-active aptazyme as an isothermally amplifiable label in an aptazyme-linked oligonucleotide assay for low-picomolar IgE detection. Analyst. 2012 Dec 21; 137(24):5710-2.
-
Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14550-5.
-
Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012 Aug; 82(4):401-11.